New, State-of-the-Art Breast Exam Tool Provides Convenient, Portable, and Efficient Access to Critical Healthcare Need
ACAP HealthWorks, in its tradition of providing unbiased solutions for employers and brokers to improve and innovate their wellbeing programs, has partnered with BexaTM, a new form of breast exam.
Bexa is an easy-to-use, handheld medical device that can be administered on-site at an employer’s location by a trained examiner. It provides a convenient, painless, and radiation-free strategy for the early detection of breast cancer. Any masses or lumps found during the Bexa breast exam are immediately evaluated with ultrasound, the results of which are then read by a board-certified radiologist. Examiners are all female technicians specially trained in the use of the Bexa device.
Bexa’s portability and efficiency, where each exam only takes about 15 minutes and can be performed anywhere, is a straightforward way to promote healthy habits, especially considering less than 40 percent of eligible woman opt to receive annual mammograms. Bexa eliminates many of the barriers related to traditional mammography, including discomfort, radiation use, delayed results, and time commitments. Additionally, because Bexa does not use radiation, it is also safe for women who are pregnant or breastfeeding.
“We know approximately 60 percent of eligible women are missing their annual mammogram due to fears of pain, radiation, intimidating clinical settings, and lack of time and resources. We have to do better, which is why this partnership is so important to us. We believe Bexa is going to be an important part of the healthcare world for years to come, and the mission and innovation behind this technology is very much in sync with our commitment to providing better health solutions at ACAP and for the employers we work with,” said Bailey Ballsrud, Chief Operating Officer, ACAP HealthWorks. “We believe in offering solutions to employers as they work to ensure their employees have the best access to care and benefits possible. We believe Bexa will revolutionize the breast exam space and encourage women to be proactive rather than reactive. I’m excited to see where this partnership will lead our efforts and what the results of Bexa will accomplish.”
Early detection of breast cancer is extremely important. If cancer is detected in stage one, the chance of 5-year survival is greater than 95 percent and treatment is less expensive. If detected in stage four, the chance of 5-year survival is 22 percent, and treatment is much more costly.
For more information on how Bexa makes early detection efforts both convenient and effective, please visit the ACAP website.
